# Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

> **NCT04819776** · PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 417 (actual)

## Conditions studied

- Bipolar I Disorder

## Interventions

- **DRUG:** Iloperidone
- **DRUG:** Iloperidone Placebo

## Key facts

- **NCT ID:** NCT04819776
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-22
- **Primary completion:** 2022-09-07
- **Final completion:** 2023-08-16
- **Target enrollment:** 417 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04819776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04819776, "Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04819776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*